Table 2. Main variants of concern and their characteristics (source: CDC.gov).
| Variant | Spike protein variant | Countries | Characteristics |
|---|---|---|---|
| Alpha | Δ69/70, Δ144Y, (E484K), (S494P), N501Y, A570D, D614G, P681H | United Kingdom | Increased transmissibility |
| No difference in antibody neutralization | |||
| Beta | K417N, E484K, N501Y, D614G | South Africa | Increased transmissibility |
| Reduced antibody neutralization | |||
| Gamma | K417N/T, E484K, N501Y, D614G | Japan, Brazil | Reduced antibody neutralization |
| Delta | T19R, L452R, T478K, P681R, D(50N) | India, worldwide | Increased transmissibility |
| Reduced antibody neutralization |